نتایج جستجو برای: fda criteria

تعداد نتایج: 273287  

Journal: :Science 2006

Journal: :Nature 1990

Journal: :Pacing and Clinical Electrophysiology 2007

Journal: :Nature Medicine 1997

Journal: :Journal of the American Academy of Audiology 2001
T K Parthasarathy B Klostermann

Similarities and differences in distortion-product otoacoustic emissions (DPOAEs) among four Food and Drug Administration (FDA) approved devices were assessed quantitatively. DPOAEs were recorded from 42 adult subjects (84 ears) ranging in age from 19 to 40 years. All subjects had hearing thresholds of 20 dB HL or better for the test frequencies from 0.25 to 8.0 kHz and normal acoustic immittan...

2013
Hui Fen Tan Ronald Low Shunsuke Ito Raymond Gregory Van Dunn

Every year, more than half a million adverse reactions to drugs are reported to the FDA. This paper is a real-world, large-scale review of beta blockers and beta agonist usage. We use New York City public hospitals’ records to investigate whether interactions of beta blockers and beta agonists are associated with increased hospital inpatient admissions, a common indicator of health care quality...

2012
Anna Lisa Crowley Han W Kim Michele Parker Deneen Spatz Brenda Hayes Lubna Bhatti Christoph J Jensen Jessica Ngo John A Papalas Patrick Pun John P Middleton Robert M Judd Raymond J Kim

Background Since 2006, the US Food and Drug Administration (FDA) has recommended restricting gadolinium based contrast agents (GBCAs) for magnetic resonance in patients with renal impairment due to an association of GBCA use with nephrogenic systemic fibrosis (NSF). The multiple FDA warnings have listed different glomerular filtration rate (GFR) cut-off values for restricting GBCA use. Conseque...

Journal: :The Journal of the American Board of Family Practice 2003
Michael W Kalsman

Home monitoring devices have been available for years, as far back as the introduction of the thermometer in the late 1800s. As technology has advanced, a large number of home monitoring devices and diagnostic tests have become available to the general public. The Food and Drug Administration (FDA) oversees this industry and has established two primary criteria for approval of such items: ease ...

Journal: :Journal of the Neurological Sciences 2015
James Anderson Christine Bell John Bishop Ishan Capila Tanmoy Ganguly Joseph Glajch Mani Iyer Ganesh Kaundinya Jonathan Lansing Joel Pradines James Prescott Bruce A. Cohen Daniel Kantor Richard Sachleben

Glatiramer acetate (GA) has been available under the brand name Copaxone® for nearly two decades. Recently, the US Food and Drug Administration (FDA) approved the first generic GA, Glatopa™, as fully substitutable for all indications for which Copaxone 20mg is approved; Glatopa also represents the first FDA-approved "AP-rated," substitutable generic for treating patients with MS. Glatiramer ace...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید